Cholangiocarcinoma 2020: the next horizon in mechanisms and management
JM Banales, JJG Marin, A Lamarca… - Nature reviews …, 2020 - nature.com
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system,
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer …
RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren… - The Lancet, 2023 - thelancet.com
Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide …
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide …
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
JN Primrose, RP Fox, DH Palmer, HZ Malik… - The Lancet …, 2019 - thelancet.com
Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ -
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …
[HTML][HTML] Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma
We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …
The implications of IDH mutations for cancer development and therapy
Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
[HTML][HTML] Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer
Cellular diversity in tumors is a key factor for therapeutic failures and lethal outcomes of solid
malignancies. Here, we determined the single-cell transcriptomic landscape of liver cancer …
malignancies. Here, we determined the single-cell transcriptomic landscape of liver cancer …
[HTML][HTML] Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma
Background & Aims Intrahepatic cholangiocarcinoma (ICC) is the second most common liver
malignancy. ICC typically features remarkable cellular heterogeneity and a dense stromal …
malignancy. ICC typically features remarkable cellular heterogeneity and a dense stromal …